Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
HBM: portfolio company Lycia achieves successful Nasdaq debut
Lycia Therapeutics raised $317.5 million in its Nasdaq IPO by issuing 17.64 million shares at $18.00 each. The stock closed on its first trading day at $30.00 (+67%). After the listing, HBM holds around 2.2% of Lycia, valued at $36.8 million; Lycia develops therapeutics for the targeted destruction of disease-causing proteins with a focus on autoimmune, inflammatory and allergic diseases. » More on finanzen.net
HBM Healthcare: half-year profit rises to around CHF 177 million
HBM Healthcare reports preliminary figures for April to September with a profit of around CHF 177 million versus CHF 96 million a year earlier. Dividend-adjusted NAV per share rose 9.8% to CHF 297.30, the share price climbed to CHF 233.50 and thus trades about 21% below NAV. Private investments contributed most to the result with CHF 138 million, including a valuation gain of CHF 74 million from a financing round at Dren Bio and CHF 32 million from the acquisition of Curevo Vaccine by Eli Lilly; listed investments contributed CHF 107 million (including Natera +CHF 41 million). Write-downs on individual private investments totaled CHF 31 million; the figures are unaudited and the final half-year report will follow on October 23. » More on finanzen.net
HBM Healthcare Investments: portfolio company Electra Therapeutics raises about $350 million in Nasdaq IPO
Electra Therapeutics went public on Nasdaq, placing 23.3 million new shares at $15.00 each, generating gross proceeds of about $350 million. HBM Healthcare Investments holds roughly 3.9% of Electra after the IPO; the stake was worth about $32.8 million based on the first trading day's closing price. Electra develops precision medicines for immune‑mediated diseases and cancer; the lead candidate, Ipsoprubart, is being tested in a global Phase‑2/3 study. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -65.09m | 125.82% |
| EBITDA | -64.73m | 8,232.93% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.59bn |
Number of shares | 6.55m |
52-week high/low | €278.94 - €212.29 |
Dividend yield | 3.84% |
Dividends TTM | €9.72 |
Beta | 0.76 |
P/E ratio | 4.25 |
PEG ratio | 0.01 |
P/B ratio | 0.76 |
P/S ratio | 7.71 |
Company profile
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.
| Name | HBM Healthcare |
| CEO | Andreas Wicki |
| Headquarters | Zug,
zg Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 14/02/2008 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
SIX | HBMN.SW |
London Stock Exchange | 0QOC.L |
Pnk | HBMBF |
Düsseldorf | 5H5A.DU |
London | 0QOC.L |
München | 5H5A.MU |